

In-House, U.S.-Based MicroSPECT/CT Imaging for Radiopharmaceutical Development

Champions Oncology now offers in-house, U.S.-based micro-SPECT/CT imaging, powered by the new Molecubes γ -X CUBE system and fully integrated with our existing oncology model platform. Radiopharmaceutical biodistribution and target engagement can be visualized and quantified within the same study, on the same models, managed by the same team already running your program. That means faster candidate screening and triage, cleaner asset comparisons, and more confident development decisions, without the delays of coordinating an outside imaging vendor.

SPECT/CT Platform

Instrument: Molecubes γ -X CUBE benchtop micro-SPECT/CT with 3-mouse hotel

Acquisition Software:
Molecubes Software Suite

Post-Processing & Analysis:
PMOD



Imaging Capabilities

- Whole-body and targeted imaging of radiolabeled compounds, so you can see where your asset actually goes, not just where it was dosed
- Longitudinal imaging across multiple study timepoints to track biodistribution changes in the same animals over time, helping reduce animal numbers versus serial-sacrifice designs
- 3D visualization of radiopharmaceutical distribution with anatomical CT coregistration to localize activity to specific organs and structures, not just general regions
- Quantitative assessment of activity distribution, generating the %ID/cc, SUV, and TAC data needed for confident go/no-go decisions
- Evaluation of tumor uptake, target engagement and organ distribution to compare candidates head-to-head on the metrics that matter for triage

Supported SPECT radionuclides: Indium-111, Lutetium-177, Terbium-161, spanning diagnostic and therapeutic isotopes across theranostic pipelines

From Imaging to Decision-Ready Data



Image and quantitative analysis TAT ~3 weeks

Quantitative Data

- %ID/cc
- Standardized uptake value (SUV)
- Time-activity curves (TACs)

Imaging Data

- Raw DICOMs
- Processed/fused SPECT/CT images

Study Reporting

- Interim data sharing
- Quantitative analysis (optional)
- Study report (optional)

An Integrated, In-House U.S. Workflow

Imaging runs executed by the same U.S.-based team using the same infrastructure as the rest of your Champions Oncology program: radiochemistry, imaging, model context, and biodistribution coordination under one roof. That gives you tighter control of your study calendar, fewer handoffs, and a faster path from imaging readout to your next decision.

One accountable team
across the core workflow

Better control of
scheduling and handoffs

Easier movement from imaging
readout to biodistribution or
efficacy follow-up

Ready to bring imaging in-house?

Contact your Champions Oncology representative to discuss how integrated SPECT/CT imaging can support your program.